PMID- 34880159
OWN - NLM
STAT- MEDLINE
DCOM- 20220125
LR  - 20220125
IS  - 1881-7823 (Electronic)
IS  - 1881-7815 (Linking)
VI  - 15
IP  - 6
DP  - 2022 Jan 23
TI  - Elevated serum CA19-9 indicates severe liver inflammation and worse survival 
      after curative resection in hepatitis B-related hepatocellular carcinoma.
PG  - 397-405
LID - 10.5582/bst.2021.01517 [doi]
AB  - We explored the prognostic value of preoperative CA19-9 in alpha-fetoprotein 
      (AFP)-positive and -negative HCC with hepatitis B virus (HBV) background 
      (HBV-HCC), and explored the underlying mechanism. Recurrence-free survival (RFS) 
      and overall survival (OS) were assessed in HBV-HCC patients who underwent 
      curative resection (Cohort 1). Immunohistochemical staining of CA19-9 in HCC and 
      liver parenchyma were quantified in another cohort of 216 patients with resected 
      HCC (Cohort 2). Immunohistochemical staining of CA19-9 and serum CA19-9 level was 
      also compared between patients with HCC and intrahepatic cholangiocarcinoma (ICC) 
      (Cohort 3). In Cohort 1, CA19-9 >/= 39 U/mL was an independent risk factor for RFS 
      (HR = 1.507, 95% CI = 1.087-2.091, p = 0.014) and OS (HR = 1.646, 95% CI = 
      1.146-2.366, p = 0.007). CA19-9 >/= 39 U/mL was also associated with significantly 
      higher incidence of macrovascular invasion (MaVI) compared with CA19-9 < 39 U/mL 
      (23.0% vs. 7.2%, p = 0.002), and elevated aminotransferase and aspartate 
      aminotransferase to platelet ratio index (APRI), and lower albumin. 
      Immunohistochemical staining of CA19-9 revealed that CA19-9 expression was found 
      exclusively in the background liver but not in HCC tumor cells. In contrast, 
      tumor tissue was the main source of CA19-9 in ICC patients. CA19-9 >/= 39 U/mL was 
      associated with worse OS and RFS in both AFP-positive and negative HCC patients. 
      CA19-9 indicated more severe inflammation and cirrhosis in the liver of HCC 
      patients.
FAU - Zhang, Wei
AU  - Zhang W
AD  - Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute 
      and Hospital; Liver Cancer Center, Tianjin Medical University Cancer Institute 
      and Hospital; National Clinical Research Center for Cancer; Key Laboratory of 
      Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for 
      Cancer, Tianjin, China.
FAU - Wang, Yingying
AU  - Wang Y
AD  - Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute 
      and Hospital; Liver Cancer Center, Tianjin Medical University Cancer Institute 
      and Hospital; National Clinical Research Center for Cancer; Key Laboratory of 
      Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for 
      Cancer, Tianjin, China.
FAU - Dong, Xiang
AU  - Dong X
AD  - Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute 
      and Hospital; Liver Cancer Center, Tianjin Medical University Cancer Institute 
      and Hospital; National Clinical Research Center for Cancer; Key Laboratory of 
      Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for 
      Cancer, Tianjin, China.
AD  - Department of Department of General Surgery, Hebei Cangzhou Hospital of 
      Integrated Traditional Chinese and Western Medicine, Cangzhou City, Hebei 
      Province, China.
FAU - Yang, Bo
AU  - Yang B
AD  - Department of Pathology, Tianjin Medical University Cancer Institute and 
      Hospital; Liver Cancer Center, Tianjin Medical University Cancer Institute and 
      Hospital; National Clinical Research Center for Cancer; Key Laboratory of Cancer 
      Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for Cancer, 
      Tianjin, China.
FAU - Zhou, Hongyuan
AU  - Zhou H
AD  - Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute 
      and Hospital; Liver Cancer Center, Tianjin Medical University Cancer Institute 
      and Hospital; National Clinical Research Center for Cancer; Key Laboratory of 
      Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for 
      Cancer, Tianjin, China.
FAU - Chen, Lu
AU  - Chen L
AD  - Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute 
      and Hospital; Liver Cancer Center, Tianjin Medical University Cancer Institute 
      and Hospital; National Clinical Research Center for Cancer; Key Laboratory of 
      Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for 
      Cancer, Tianjin, China.
FAU - Zhang, Zewu
AU  - Zhang Z
AD  - Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute 
      and Hospital; Liver Cancer Center, Tianjin Medical University Cancer Institute 
      and Hospital; National Clinical Research Center for Cancer; Key Laboratory of 
      Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for 
      Cancer, Tianjin, China.
FAU - Zhang, Qin
AU  - Zhang Q
AD  - Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute 
      and Hospital; Liver Cancer Center, Tianjin Medical University Cancer Institute 
      and Hospital; National Clinical Research Center for Cancer; Key Laboratory of 
      Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for 
      Cancer, Tianjin, China.
FAU - Cao, Guangtai
AU  - Cao G
AD  - Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute 
      and Hospital; Liver Cancer Center, Tianjin Medical University Cancer Institute 
      and Hospital; National Clinical Research Center for Cancer; Key Laboratory of 
      Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for 
      Cancer, Tianjin, China.
FAU - Han, Zhiqiang
AU  - Han Z
AD  - Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute 
      and Hospital; Liver Cancer Center, Tianjin Medical University Cancer Institute 
      and Hospital; National Clinical Research Center for Cancer; Key Laboratory of 
      Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for 
      Cancer, Tianjin, China.
FAU - Li, Huikai
AU  - Li H
AD  - Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute 
      and Hospital; Liver Cancer Center, Tianjin Medical University Cancer Institute 
      and Hospital; National Clinical Research Center for Cancer; Key Laboratory of 
      Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for 
      Cancer, Tianjin, China.
FAU - Cui, Yunlong
AU  - Cui Y
AD  - Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute 
      and Hospital; Liver Cancer Center, Tianjin Medical University Cancer Institute 
      and Hospital; National Clinical Research Center for Cancer; Key Laboratory of 
      Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for 
      Cancer, Tianjin, China.
FAU - Wu, Qiang
AU  - Wu Q
AD  - Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute 
      and Hospital; Liver Cancer Center, Tianjin Medical University Cancer Institute 
      and Hospital; National Clinical Research Center for Cancer; Key Laboratory of 
      Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for 
      Cancer, Tianjin, China.
FAU - Zhang, Ti
AU  - Zhang T
AD  - Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute 
      and Hospital; Liver Cancer Center, Tianjin Medical University Cancer Institute 
      and Hospital; National Clinical Research Center for Cancer; Key Laboratory of 
      Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for 
      Cancer, Tianjin, China.
FAU - Song, Tianqiang
AU  - Song T
AD  - Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute 
      and Hospital; Liver Cancer Center, Tianjin Medical University Cancer Institute 
      and Hospital; National Clinical Research Center for Cancer; Key Laboratory of 
      Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for 
      Cancer, Tianjin, China.
FAU - Li, Qiang
AU  - Li Q
AD  - Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute 
      and Hospital; Liver Cancer Center, Tianjin Medical University Cancer Institute 
      and Hospital; National Clinical Research Center for Cancer; Key Laboratory of 
      Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for 
      Cancer, Tianjin, China.
LA  - eng
PT  - Journal Article
DEP - 20211209
PL  - Japan
TA  - Biosci Trends
JT  - Bioscience trends
JID - 101502754
RN  - 0 (CA-19-9 Antigen)
SB  - IM
MH  - *Bile Duct Neoplasms
MH  - Bile Ducts, Intrahepatic
MH  - CA-19-9 Antigen
MH  - *Carcinoma, Hepatocellular/surgery
MH  - *Hepatitis B
MH  - Humans
MH  - Inflammation
MH  - *Liver Neoplasms/surgery
MH  - Retrospective Studies
OTO - NOTNLM
OT  - EpCAM
OT  - carbohydrate antigen 19-9
OT  - hepatocellular carcinoma
OT  - survival
OT  - alpha-fetoprotein
EDAT- 2021/12/10 06:00
MHDA- 2022/01/27 06:00
CRDT- 2021/12/09 05:50
PHST- 2021/12/10 06:00 [pubmed]
PHST- 2022/01/27 06:00 [medline]
PHST- 2021/12/09 05:50 [entrez]
AID - 10.5582/bst.2021.01517 [doi]
PST - ppublish
SO  - Biosci Trends. 2022 Jan 23;15(6):397-405. doi: 10.5582/bst.2021.01517. Epub 2021 
      Dec 9.